Inhibitors of Bruton's tyrosine kinase
Granted 20 Oct 2015 · 4 office actions
Current assignee: Pharmacyclics · originally AbbVie Inc.
Law firm: Law firm · Log in to unlock
Attorney: Attorney · Log in to unlock
Inventors: Zhengying Pan, Lee Honigberg, Erik Verner · Examiner: Jeffrey H Murray · AU 1624 · TC 1600
Life of the patent
4 dated eventsAbstract
Disclosed herein are compounds of Formula (D) that form covalent bonds with Bruton\'s tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. [structure]
Claims
4 · 2 independent · depth 3Classifications
6 codes- A01N43/90
- A61K31/519
- A61K9/48
- A61K45/06
- A61K31/00
- C07D487/04
Claim changes
SoonSee which claims were amended, added or cancelled during examination, with every added and removed word marked.
The published claims of this patent are not paired with the granted ones in what we hold.
File wrapper
See the full prosecution history — every USPTO and applicant action on this file, in order.
Log in to unlockTerm & fees
See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.
Log in to unlockPriority chain
2 priority documents›Priority documents — 2
| Type | Document | Date |
|---|---|---|
| provisional | US 60826720 | 22 Sep 2006 |
| related publication | US 20140187565 A1 | 3 Jul 2014 |
Validity challenges
See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.
Log in to unlockCitations
See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.
Log in to unlock